ZA96449B - Guanine derivative - Google Patents

Guanine derivative

Info

Publication number
ZA96449B
ZA96449B ZA96449A ZA96449A ZA96449B ZA 96449 B ZA96449 B ZA 96449B ZA 96449 A ZA96449 A ZA 96449A ZA 96449 A ZA96449 A ZA 96449A ZA 96449 B ZA96449 B ZA 96449B
Authority
ZA
South Africa
Prior art keywords
guanine derivative
guanine
derivative
Prior art date
Application number
ZA96449A
Other languages
English (en)
Inventor
Barry Howard Carter
Peter Gregory Varlashkin
William Bayne Grubb Iii
Philip George Lake
David James Whatrup
Jane Muse Partin
Richard Augustus Winnike
Gregory Alan Conway
David Michael Skinner
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA96449(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of ZA96449B publication Critical patent/ZA96449B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA96449A 1995-01-20 1996-01-19 Guanine derivative ZA96449B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
ZA96449B true ZA96449B (en) 1996-08-07

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96449A ZA96449B (en) 1995-01-20 1996-01-19 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (en:Method)
EP (1) EP0804436B1 (en:Method)
JP (1) JP3176633B2 (en:Method)
KR (1) KR100376074B1 (en:Method)
CN (1) CN1049893C (en:Method)
AP (1) AP662A (en:Method)
AR (1) AR002270A1 (en:Method)
AT (1) ATE302777T1 (en:Method)
AU (1) AU702794B2 (en:Method)
BG (1) BG63393B1 (en:Method)
BR (1) BR9606768A (en:Method)
CA (1) CA2210799C (en:Method)
CY (1) CY2531B1 (en:Method)
CZ (1) CZ297065B6 (en:Method)
DE (1) DE69635106T2 (en:Method)
DK (1) DK0804436T3 (en:Method)
EA (1) EA000364B1 (en:Method)
EE (1) EE03528B1 (en:Method)
ES (1) ES2248806T3 (en:Method)
FI (1) FI973063A7 (en:Method)
GB (1) GB9501178D0 (en:Method)
GE (1) GEP20001940B (en:Method)
HR (1) HRP960024B1 (en:Method)
HU (1) HU222993B1 (en:Method)
IL (1) IL116831A (en:Method)
IN (1) IN182468B (en:Method)
IS (1) IS2268B (en:Method)
NO (1) NO315558B1 (en:Method)
NZ (1) NZ298851A (en:Method)
OA (1) OA10499A (en:Method)
PL (1) PL182175B1 (en:Method)
RO (1) RO118693B1 (en:Method)
RS (1) RS49518B (en:Method)
SI (1) SI0804436T1 (en:Method)
SK (1) SK285329B6 (en:Method)
TR (1) TR199700656T1 (en:Method)
UA (1) UA46001C2 (en:Method)
UY (1) UY25779A1 (en:Method)
WO (1) WO1996022291A1 (en:Method)
ZA (1) ZA96449B (en:Method)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
AU722304B2 (en) * 1996-01-19 2000-07-27 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (fr) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Nouveaux cristaux de z-valacyclovir
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
CZ2004446A3 (cs) * 2001-09-07 2005-01-12 Teva Pharmaceutical Industries Ltd. Krystalické formy valaciklovir hydrochloridu
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
EP1706406A1 (en) * 2004-01-21 2006-10-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1976933A (zh) * 2004-06-30 2007-06-06 特瓦制药工业有限公司 减少晶体盐酸伐昔洛韦中的残留醇的方法
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20110235A1 (es) * 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2016079A1 (de) 2006-05-04 2009-01-21 Boehringer Ingelheim International GmbH Polymorphe
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
AP662A (en) 1998-08-19
FI973063L (fi) 1997-09-18
EA000364B1 (ru) 1999-06-24
EA199700124A1 (ru) 1997-12-30
CZ297065B6 (cs) 2006-08-16
AR002270A1 (es) 1998-03-11
UY25779A1 (es) 2000-08-21
CA2210799A1 (en) 1996-07-25
TR199700656T1 (xx) 1998-03-21
DE69635106D1 (de) 2005-09-29
JPH11503718A (ja) 1999-03-30
OA10499A (en) 2002-04-10
US6107302A (en) 2000-08-22
UA46001C2 (uk) 2002-05-15
ATE302777T1 (de) 2005-09-15
MX9705462A (es) 1997-10-31
NZ298851A (en) 1999-01-28
CA2210799C (en) 2008-06-10
FI973063A0 (fi) 1997-07-18
CZ229497A3 (en) 1997-12-17
CY2531B1 (en) 2006-04-12
BR9606768A (pt) 1997-12-30
NO973326D0 (no) 1997-07-18
SI0804436T1 (sl) 2006-02-28
KR19980701525A (ko) 1998-05-15
RO118693B1 (ro) 2003-09-30
FI973063A7 (fi) 1997-09-18
JP3176633B2 (ja) 2001-06-18
WO1996022291A1 (en) 1996-07-25
AU4453996A (en) 1996-08-07
PL182175B1 (pl) 2001-11-30
GEP20001940B (en) 2000-02-05
EE03528B1 (et) 2001-10-15
KR100376074B1 (ko) 2003-06-02
IS2268B (is) 2007-07-15
HRP960024A2 (en) 1997-10-31
BG101833A (bg) 1998-04-30
IL116831A0 (en) 1996-05-14
AP9701058A0 (en) 1997-10-31
HU222993B1 (hu) 2004-01-28
CN1179159A (zh) 1998-04-15
NO973326L (no) 1997-09-16
SK285329B6 (sk) 2006-11-03
IN182468B (en:Method) 1999-04-17
YU3396A (sh) 1998-12-23
HRP960024B1 (en) 2005-08-31
GB9501178D0 (en) 1995-03-08
EE9700175A (et) 1998-02-16
DK0804436T3 (da) 2005-12-27
ES2248806T3 (es) 2006-03-16
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
EP0804436A1 (en) 1997-11-05
RS49518B (sr) 2006-10-27
AU702794B2 (en) 1999-03-04
HUP9801836A2 (hu) 1999-05-28
IS4527A (is) 1997-07-15
SK96597A3 (en) 1998-02-04
IL116831A (en) 1998-10-30
EP0804436B1 (en) 2005-08-24
NO315558B1 (no) 2003-09-22
DE69635106T2 (de) 2006-06-08
HUP9801836A3 (en) 1999-06-28
PL321326A1 (en) 1997-12-08

Similar Documents

Publication Publication Date Title
GB9501178D0 (en) Guanine derivative
GB9508565D0 (en) Quiazoline derivative
NZ305444A (en) 4-anilino-7-alkoxy-quinazoline derivatives
IL152383A0 (en) 5-amino-3-cyano-4-ethylsulfinyl-1- phenyl-pyrazole derivatives
IL135376A0 (en) Hydroxyalkyl-phenyl derivatives
GB2306473A8 (en) Glucoxide derivatives
ZA96228B (en) Indolepiperidine derivatives
HU9603071D0 (en) Purin-6-one derivatives
HU9600876D0 (en) Benzonitril- and -fluoride derivatives
HUP9600107A3 (en) 9-substituted-2-(2-n-alkoxy-phenyl)-purin-6-one derivatives
NZ332395A (en) Benzonthiazole derivatives
SI0758644T1 (en) Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives
HUP9900672A3 (en) Pyrroloazepine derivatives
SG60005A1 (en) 1-Fluorocyclohexene-difluorophenyl derivatives
IL123621A0 (en) Diarylalkenylamine derivatives
GR3035577T3 (en) Benzisothiazolyl-substituted aminomethylchroman derivatives
ZA964470B (en) Cycloalkane-benzylidene derivatives
IL117858A0 (en) 4-Indolypiperazinyl derivatives
ZA96629B (en) 4-Aminobenzolylguanidine derivatives
HU9602324D0 (en) Piperidinyl-methyl-oxazolidinon derivatives
EP0754668A3 (de) Fluorbenzylether-Derivate
GB9516349D0 (en) Aza-anthracyclinone derivatives
ZA967204B (en) Alkenyl-benzoylguanidine derivatives
ZA96701B (en) 4-Mercaptobenzoylgaunidine derivatives
EP0804205A4 (en) 4-AZA-19-NORANDROSTANDERIVATE